326 related articles for article (PubMed ID: 36069174)
1. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis.
Fragoulis GE; Siebert S
Musculoskeletal Care; 2022 Nov; 20 Suppl 1(Suppl 1):S12-S21. PubMed ID: 36069174
[TBL] [Abstract][Full Text] [Related]
2. IL-23 inhibition for the treatment of psoriatic arthritis.
Mohanakrishnan R; Beier S; Deodhar A
Expert Opin Biol Ther; 2022 Jan; 22(1):59-65. PubMed ID: 34092169
[TBL] [Abstract][Full Text] [Related]
3. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
Boehncke WH; Brembilla NC; Nissen MJ
Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for differential p19 targeting by IL-23 biologics.
Daniele SG; Eldirany SA; Ho M; Bunick CG
bioRxiv; 2023 Mar; ():. PubMed ID: 36945513
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
Thibodaux RJ; Triche MW; Espinoza LR
Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
[TBL] [Abstract][Full Text] [Related]
6. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
Blauvelt A; Chiricozzi A; Ehst BD; Lebwohl MG
Adv Ther; 2023 Aug; 40(8):3410-3433. PubMed ID: 37330926
[TBL] [Abstract][Full Text] [Related]
7. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
[TBL] [Abstract][Full Text] [Related]
9. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab for the Treatment of Psoriasis.
Machado Á; Torres T
BioDrugs; 2018 Apr; 32(2):119-128. PubMed ID: 29470778
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL 23 biologics for the treatment of plaque psoriasis.
Vu A; Ulschmid C; Gordon KB
Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011
[TBL] [Abstract][Full Text] [Related]
12. Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.
Kavanaugh A; Baraliakos X; Gao S; Chen W; Sweet K; Chakravarty SD; Song Q; Shawi M; Rahman P
Adv Ther; 2023 May; 40(5):2439-2456. PubMed ID: 36995469
[TBL] [Abstract][Full Text] [Related]
13. Risankizumab in Adults with Psoriatic Arthritis.
Machlab K; Yeung J; Gooderham M
Skin Therapy Lett; 2023 Nov; 28(6):1-6. PubMed ID: 38015960
[TBL] [Abstract][Full Text] [Related]
14. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis.
Elgaard CDB; Iversen L; Hjuler KF
J Dermatolog Treat; 2023 Dec; 34(1):2133531. PubMed ID: 36200762
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials.
Huang X; Shentu H; He Y; Lai H; Xu C; Chen M; Zhu H
Immunol Res; 2023 Aug; 71(4):505-515. PubMed ID: 36811818
[TBL] [Abstract][Full Text] [Related]
16. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
17. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Yang K; Oak ASW; Elewski BE
Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128
[TBL] [Abstract][Full Text] [Related]
18. IL-23 and axial disease: do they come together?
Mease P; van den Bosch F
Rheumatology (Oxford); 2021 Oct; 60(Suppl 4):iv28-iv33. PubMed ID: 34668015
[TBL] [Abstract][Full Text] [Related]
19. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
Braun J; Landewé RB
Ann Rheum Dis; 2022 Apr; 81(4):466-468. PubMed ID: 34656991
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.
Torres T; Faria R
Drug Dev Res; 2015 Dec; 76(8):428-31. PubMed ID: 26372543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
